Active, not recruitingPHASE1, PHASE2NCT02935361
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Studying Acute myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Southern California
- Principal Investigator
- Casey O'ConnellUniversity of Southern California
- Intervention
- Atezolizumab(drug)
- Enrollment
- 33 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2027
Study locations (4)
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of Maryland Medical Center, Baltimore, Maryland, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- Temple University Hospital, Philadelphia, Pennsylvania, United States
Collaborators
National Cancer Institute (NCI) · Van Andel Research Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02935361 on ClinicalTrials.govOther trials for Acute myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasCrossbow Therapeutics, Inc.
- RECRUITINGPHASE2NCT06680661ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisLeland Metheny
- RECRUITINGPHASE2NCT06778187Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong Kong
- RECRUITINGPHASE1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology Group
- RECRUITINGNCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT05807932Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE1NCT05636514Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSClinical Hub for Interventional Research (CHOIR)
- RECRUITINGPHASE1, PHASE2NCT05092451Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer Center